• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Rubius snags $120m for red blood cell therapeutics

June 21, 2017 By Sarah Faulkner

Rubius TherapeuticsRubius Therapeutics, a biotech engineering red blood cells as drug carriers, said today that it raised $120 million in an oversubscribed private financing round.

The Cambridge, Mass.-based company plans to use its newly-acquired funds to support its Red-Cell Therapeutics portfolio and prepare for human clinical trials in 2018.

“With this financing, Rubius is well positioned to focus on the continued development of our platform to advance a broad range of therapeutic candidates that have the potential to make a significant difference in the lives of patients,” president Torben Straight Nissen said in prepared remarks.

“Rubius has achieved multiple scientific and manufacturing milestones in the first 6 months of this year. Those achievements plus the trust that Flagship and our new investors have put in Rubius with this financing sets us up to turn our RCTs into important new treatment options,” chairman David Epstein added. Epstein is also the executive partner of Flagship Pioneering, which launched Rubius 2 years ago and continues to fund the company.

The Red-Cell Therapeutics platform combines red blood cells with enzymes, agonists, antagonists and binders in their natural conformation. The company said that its lead programs include enzyme replacement therapies and treatments targeting solid tumors and hematological cancers.

“We are excited to expand our support of Rubius in this next round of funding as the company continues to advance its technology and programs — following in the footsteps of Flagship’s family of successful multiproduct platform companies,” Rubius co-founder & CEO of Flagship Pioneering, Noubar Afeyan, said. “The team at Rubius has made great strides over the past 3 years and we are pleased to support the company’s continued growth. This new financing, together with a leadership team with unparalleled expertise, positions Rubius to deliver on the promise of the RCT platform and bring transformative therapies to patients.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Clinical Trials, Featured, Funding Roundup, Oncology, Pharmaceuticals, Research & Development Tagged With: rubiustherapeutics

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS